DE60008262D1 - Piperazinderivate als 5-ht1b antagonisten - Google Patents

Piperazinderivate als 5-ht1b antagonisten

Info

Publication number
DE60008262D1
DE60008262D1 DE60008262T DE60008262T DE60008262D1 DE 60008262 D1 DE60008262 D1 DE 60008262D1 DE 60008262 T DE60008262 T DE 60008262T DE 60008262 T DE60008262 T DE 60008262T DE 60008262 D1 DE60008262 D1 DE 60008262D1
Authority
DE
Germany
Prior art keywords
piperazine derivatives
ht1b antagonists
ht1b
antagonists
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60008262T
Other languages
English (en)
Other versions
DE60008262T2 (de
Inventor
Howard Marshall
Mervyn Thompson
Paul Adrian Wyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922831.4A external-priority patent/GB9922831D0/en
Priority claimed from GB0001936A external-priority patent/GB0001936D0/en
Priority claimed from GB0013873A external-priority patent/GB0013873D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60008262D1 publication Critical patent/DE60008262D1/de
Publication of DE60008262T2 publication Critical patent/DE60008262T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60008262T 1999-09-25 2000-09-21 Piperazinderivate als 5-ht1b antagonisten Expired - Fee Related DE60008262T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9922831.4A GB9922831D0 (en) 1999-09-25 1999-09-25 Novel compounds
GB9922831 1999-09-25
GB0001936 2000-01-27
GB0001936A GB0001936D0 (en) 2000-01-27 2000-01-27 Novel compounds
GB0013873A GB0013873D0 (en) 2000-06-07 2000-06-07 Novel compounds
GB0013873 2000-06-07
PCT/EP2000/009442 WO2001023374A1 (en) 1999-09-25 2000-09-21 Piperazine derivatives as 5-ht1b antagonists

Publications (2)

Publication Number Publication Date
DE60008262D1 true DE60008262D1 (de) 2004-03-18
DE60008262T2 DE60008262T2 (de) 2004-12-16

Family

ID=27255501

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60008262T Expired - Fee Related DE60008262T2 (de) 1999-09-25 2000-09-21 Piperazinderivate als 5-ht1b antagonisten

Country Status (27)

Country Link
US (2) US6747030B1 (de)
EP (1) EP1216239B1 (de)
JP (1) JP2003510317A (de)
KR (1) KR20020030126A (de)
CN (1) CN1190432C (de)
AR (1) AR029454A1 (de)
AT (1) ATE259363T1 (de)
AU (1) AU765020B2 (de)
BR (1) BR0014279A (de)
CA (1) CA2385737A1 (de)
CO (1) CO5200839A1 (de)
CZ (1) CZ20021038A3 (de)
DE (1) DE60008262T2 (de)
DK (1) DK1216239T3 (de)
ES (1) ES2211624T3 (de)
HK (1) HK1046909B (de)
HU (1) HUP0202787A3 (de)
IL (1) IL148818A0 (de)
MX (1) MXPA02003175A (de)
MY (1) MY122391A (de)
NO (1) NO20021459D0 (de)
NZ (1) NZ517865A (de)
PE (1) PE20010641A1 (de)
PL (1) PL362900A1 (de)
PT (1) PT1216239E (de)
TR (1) TR200200795T2 (de)
WO (1) WO2001023374A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014279A (pt) * 1999-09-25 2002-05-21 Smithkline Beecham Plc Derivados de piperazina como antagonistas 5-ht1b
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
WO2002042273A2 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
GB0106419D0 (en) * 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
GB0106586D0 (en) * 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
MXPA05013756A (es) 2003-06-18 2006-03-08 Pfizer Prod Inc Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas.
RU2007107349A (ru) 2004-07-28 2008-09-10 Глэксо Груп Лимитед (GB) Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
PE20080176A1 (es) 2006-03-31 2008-04-25 Glaxo Group Ltd Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
US8921124B2 (en) 2006-03-31 2014-12-30 Wako Pure Chemical Industries, Ltd. Pyrazole-based cyanine dye
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN102766139B (zh) * 2012-08-14 2014-09-17 江苏先声药物研究有限公司 阿齐沙坦的多晶型物及其制备方法
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3139930A4 (de) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salze und polymorphe von cyclischen borsäureesterderivaten und therapeutische verwendungen davon
EP4356736A2 (de) 2014-05-05 2024-04-24 Melinta Therapeutics, Inc. Synthese von boronatsalzen
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
GB2532990A (en) 2014-12-05 2016-06-08 Schlumberger Holdings Corrosion inhibition
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
GB2543498A (en) * 2015-10-19 2017-04-26 Schlumberger Holdings Corrosion inhibition
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
IL273551B2 (en) 2017-10-11 2024-02-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
US5696122A (en) * 1993-09-03 1997-12-09 Smithkline Beecham P.L.C. Indole and indoline derivatives as 5HT1D receptor antagonists
CA2274055A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham P.L.C. N-piperazin-1-ylphenyl-benzamide derivatives
CN1260781A (zh) * 1997-04-18 2000-07-19 史密丝克莱恩比彻姆有限公司 具有综合的5ht1a、5ht1b和5ht1d受体拮抗剂活性的吲哚衍生物
JP2001526643A (ja) * 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
GB9725931D0 (en) * 1997-12-05 1998-02-04 Smithkline Beecham Plc Novel compounds
BR0014279A (pt) * 1999-09-25 2002-05-21 Smithkline Beecham Plc Derivados de piperazina como antagonistas 5-ht1b

Also Published As

Publication number Publication date
CN1190432C (zh) 2005-02-23
PE20010641A1 (es) 2001-07-14
AU765020B2 (en) 2003-09-04
HUP0202787A2 (hu) 2002-12-28
PT1216239E (pt) 2004-05-31
HK1046909A1 (en) 2003-01-30
MXPA02003175A (es) 2002-09-30
US20040176388A1 (en) 2004-09-09
ES2211624T3 (es) 2004-07-16
CZ20021038A3 (cs) 2002-08-14
AU7783600A (en) 2001-04-30
CN1399635A (zh) 2003-02-26
ATE259363T1 (de) 2004-02-15
TR200200795T2 (tr) 2002-07-22
HUP0202787A3 (en) 2003-12-29
EP1216239A1 (de) 2002-06-26
US6747030B1 (en) 2004-06-08
DE60008262T2 (de) 2004-12-16
NO20021459L (no) 2002-03-22
EP1216239B1 (de) 2004-02-11
AR029454A1 (es) 2003-07-02
NO20021459D0 (no) 2002-03-22
MY122391A (en) 2006-04-29
IL148818A0 (en) 2002-09-12
CO5200839A1 (es) 2002-09-27
CA2385737A1 (en) 2001-04-05
BR0014279A (pt) 2002-05-21
NZ517865A (en) 2003-11-28
PL362900A1 (en) 2004-11-02
WO2001023374A1 (en) 2001-04-05
HK1046909B (zh) 2004-12-03
KR20020030126A (ko) 2002-04-22
DK1216239T3 (da) 2004-06-14
JP2003510317A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
ATE259363T1 (de) Piperazinderivate als 5-ht1b antagonisten
ATE299865T1 (de) Piperazinderivate verwendbar als ccr5 antagonisten
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
DE60012031D1 (de) Piperazin verbindungen als tachykinin-antagonisten
DE50001729D1 (de) N-(indolcarbonyl-)piperazinderivate als 5-ht2a-rezeptor liganden
IS6546A (is) Nýjar píperazín afleiður
ATE397595T1 (de) Piperazin-derivate
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
NO20023293D0 (no) Piperidin- og piperazinderivater som virker som 5-HT2A- reseptorantagonister
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
NO20031572D0 (no) Brodannete piperazinderivater
DE60004017D1 (de) Heterocyclische benzolsulfonamidderivate als bradykinin antagonisten
ATE254621T1 (de) Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
DE60017110D1 (de) Biphenylderivate als neurokinin-1 antagonisten
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
DE60230491D1 (de) Als ccr5-antagonisten verwendbare aryloxim-piperazine
ATE506357T1 (de) Heterocyclische aminoalkylpyridinderivate als psychopharmaka
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten
ATE305005T1 (de) Piperazinderivative als tachykinin antagonisten
SI1216239T1 (en) Piperazine derivatives as 5-ht1b antagonists
PT1131308E (pt) Novos compostos de piperazina e piperidina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee